ES2721031T3 - Compuestos de dihidroisoquinolinona sustituidos - Google Patents
Compuestos de dihidroisoquinolinona sustituidos Download PDFInfo
- Publication number
- ES2721031T3 ES2721031T3 ES15730290T ES15730290T ES2721031T3 ES 2721031 T3 ES2721031 T3 ES 2721031T3 ES 15730290 T ES15730290 T ES 15730290T ES 15730290 T ES15730290 T ES 15730290T ES 2721031 T3 ES2721031 T3 ES 2721031T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- cycloalkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
Un compuesto de formula (I):**Fórmula** o una sal farmacéuticamente aceptable del mismo, en la que: R1 se selecciona del grupo que consiste en F, alquilo C1-C4, alcoxi C1-C4, C(O)R5, cicloalquilo C3-C8, heterociclilo de 3-12 miembros y heteroarilo de 5-12 miembros, en la que cada alquilo C1-C4 o alcoxi C1-C4 está opcionalmente sustituido con uno o más R6, y cada uno de dichos cicloalquilo C3-C8, heterociclilo de 3-12 miembros o heteroarilo de 5-12 miembros está opcionalmente sustituido con uno o más R7; R2 es H, F o alquilo C1-C4; L es un enlace o un alquileno C1-C4; R3 se selecciona del grupo que consiste en alquilo C1-C4, alcoxi C1-C4, OH, CN, C(O)R8, COOR9, NR10R11, OR12, cicloalquilo C3-C8, heterociclilo de 3-12 miembros y heteroarilo de 5-12 miembros, en la que cada uno de dichos alquilo C1-C4 o alcoxi C1-C4 está opcionalmente sustituido con uno o más R6, y cada uno de dichos cicloalquilo C3-C8, heterociclilo de 3-12 miembros o heteroarilo de 5-12 miembros está opcionalmente sustituido con uno o más R7; R4 es H, halo o alquilo C1-C4, en la que cada alquilo C1-C4 está opcionalmente sustituido con uno o más R6; R5 es alquilo C1-C4, en la que cada alquilo C1-C4 está opcionalmente sustituido con uno o más R14; cada R6 es independientemente OH, F, CN o alcoxi C1-C4; cada R7 es independientemente alquilo C1-C4, OH, F, CN, alcoxi C1-C4, =O, o C(O)R13; R8 es alquilo C1-C4, en la que cada alquilo C1-C4 está opcionalmente sustituido con uno o más R14; R9 es H o alquilo C1-C4, en la que cada alquilo C1-C4 está opcionalmente sustituido con uno o más R14; R10 y R11 son independientemente H o alquilo C1-C4, en la que cada alquilo C1-C4 está opcionalmente sustituido con uno o más R14; R12 se selecciona del grupo que consiste en cicloalquilo C3-C8, heterociclilo de 3-12 miembros y heteroarilo de 5-12 miembros, en la que cada uno de dichos cicloalquilo C3-C8, heterociclilo de 3-12 miembros o heteroarilo de 5-12 miembros está opcionalmente sustituido con uno o más R7; cada R13 es independientemente alquilo C1-C4, en la que cada alquilo C1-C4 está opcionalmente sustituido con uno o más R15; cada R14 y R15 es independientemente OH, F, CN o alcoxi C1-C4; y X y Z son independientemente alquilo C1-C4, fluoroalquilo C1-C4, alcoxi C1-C4 o fluoroalcoxi C1-C4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013410P | 2014-06-17 | 2014-06-17 | |
| US201562156533P | 2015-05-04 | 2015-05-04 | |
| PCT/IB2015/054272 WO2015193765A1 (en) | 2014-06-17 | 2015-06-05 | Substituted dihydroisoquinolinone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2721031T3 true ES2721031T3 (es) | 2019-07-26 |
Family
ID=53434412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15730290T Active ES2721031T3 (es) | 2014-06-17 | 2015-06-05 | Compuestos de dihidroisoquinolinona sustituidos |
Country Status (40)
| Country | Link |
|---|---|
| US (4) | US9481666B2 (es) |
| EP (2) | EP3157915B1 (es) |
| JP (1) | JP6152495B1 (es) |
| KR (1) | KR101877187B1 (es) |
| CN (1) | CN107207464B (es) |
| AP (1) | AP2016009605A0 (es) |
| AU (1) | AU2015275826B2 (es) |
| BR (1) | BR112016029612B1 (es) |
| CA (1) | CA2894298C (es) |
| CL (1) | CL2016003246A1 (es) |
| CR (2) | CR20200484A (es) |
| CU (1) | CU24408B1 (es) |
| CY (1) | CY1121706T1 (es) |
| DK (1) | DK3157915T3 (es) |
| EA (1) | EA031892B1 (es) |
| ES (1) | ES2721031T3 (es) |
| GE (1) | GEP20186933B (es) |
| HR (1) | HRP20190604T1 (es) |
| HU (1) | HUE042964T2 (es) |
| IL (1) | IL248991B (es) |
| LT (1) | LT3157915T (es) |
| MA (1) | MA40225B1 (es) |
| MD (1) | MD4820C1 (es) |
| ME (1) | ME03419B (es) |
| MX (1) | MX2016016764A (es) |
| MY (1) | MY185765A (es) |
| NZ (1) | NZ726108A (es) |
| PE (1) | PE20161552A1 (es) |
| PH (1) | PH12016502378A1 (es) |
| PL (1) | PL3157915T3 (es) |
| PT (1) | PT3157915T (es) |
| RS (1) | RS58632B1 (es) |
| SG (1) | SG11201609386YA (es) |
| SI (1) | SI3157915T1 (es) |
| SV (1) | SV2016005333A (es) |
| TN (1) | TN2016000529A1 (es) |
| TW (1) | TWI561516B (es) |
| UA (1) | UA118380C2 (es) |
| UY (1) | UY36170A (es) |
| WO (1) | WO2015193765A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| CU24408B1 (es) | 2014-06-17 | 2019-05-03 | Pfizer | Compuestos de dihidroisoquinolinona sustituida |
| TW201708210A (zh) * | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產（第二）有限公司 | Ｚｅｓｔｅ同源物２增強子之抑制劑 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10604531B2 (en) | 2016-05-05 | 2020-03-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| US20210147381A1 (en) | 2017-07-17 | 2021-05-20 | AbbVie Deutschland GmbH & Co. KG | 1,2,3,4-substituted quinoline compounds as sip modulators |
| TWI698238B (zh) | 2017-11-14 | 2020-07-11 | 美商輝瑞股份有限公司 | Ｅｚｈ２抑制劑組合治療 |
| PT3746446T (pt) | 2018-01-31 | 2022-07-18 | Mirati Therapeutics Inc | Inibidores de prc2 |
| UA127357C2 (uk) | 2018-04-18 | 2023-07-26 | Констеллатіон Фармацеутікалс, Інк. | Модулятори метилмодифікуючих ферментів, композиції та їх використання |
| US11919912B2 (en) | 2018-05-21 | 2024-03-05 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN112399857A (zh) | 2018-07-09 | 2021-02-23 | 盲人庇护基金会 | Prc2亚单位的抑制治疗眼失调 |
| WO2020086857A1 (en) * | 2018-10-24 | 2020-04-30 | Vanderbilt University | Wdr5 inhibitors and modulators |
| KR20200101219A (ko) * | 2019-02-19 | 2020-08-27 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
| WO2022018594A1 (en) | 2020-07-20 | 2022-01-27 | Pfizer Inc. | Synthesis of novel intermediates for substituted 3,4-dihydroisoquinolinones |
| US20240101535A1 (en) * | 2020-12-11 | 2024-03-28 | Etern Biopharma (Shanghai) Co., Ltd. | Dihydroisoquinolinone derivative and application thereof |
| WO2023098880A1 (zh) * | 2021-12-02 | 2023-06-08 | 上海翰森生物医药科技有限公司 | 稠环类衍生物调节剂、其制备方法和应用 |
| WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3846412A (en) | 1971-03-18 | 1974-11-05 | Lepetit Spa | Dihydro-2-amino-isoquinolines and their derivatives |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| EP1940819A1 (en) | 2005-08-16 | 2008-07-09 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
| WO2007075783A2 (en) * | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| US8569298B2 (en) * | 2008-06-17 | 2013-10-29 | Astrazeneca Ab | Pyridine compounds |
| US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| US20110251216A1 (en) | 2010-02-19 | 2011-10-13 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| EP2566328B1 (en) | 2010-05-07 | 2015-03-04 | GlaxoSmithKline LLC | Indazoles |
| US8637509B2 (en) | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| PL2566327T3 (pl) | 2010-05-07 | 2017-09-29 | Glaxosmithkline Llc | Indole |
| CA2810998C (en) | 2010-09-10 | 2024-04-09 | Robert Allen Copeland | Inhibitors of human ezh2, and methods of use thereof |
| CN103108871B (zh) * | 2010-09-16 | 2014-09-10 | 诺华股份有限公司 | 17α-羟化酶/C17,20-裂合酶抑制剂 |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2681216B1 (en) | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TWI598336B (zh) * | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| US9730925B2 (en) | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
| WO2013059944A1 (en) * | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Epigenetic regulators and uses thereof |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| EP2900653A1 (en) | 2012-09-28 | 2015-08-05 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| PL3067358T3 (pl) | 2012-12-21 | 2020-02-28 | Gilead Sciences, Inc. | Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne |
| JP6067878B2 (ja) | 2012-12-21 | 2017-01-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | オキシトシンアゴニストとしてのペプチド |
| FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
| CA2895239C (en) | 2012-12-21 | 2020-10-27 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| UA111305C2 (uk) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| HUE038748T2 (hu) | 2012-12-21 | 2018-11-28 | Sanofi Sa | Exendin-4 származékok, mint duális GLP1/GIP- vagy trigonális GLP1/GIP/glukagon-agonisták |
| FR3000059A1 (fr) | 2012-12-21 | 2014-06-27 | Saint Gobain Placo | Composition pour plaques de platre et produits obtenus |
| SG11201504554UA (en) | 2012-12-21 | 2015-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| JP6678455B2 (ja) | 2012-12-21 | 2020-04-08 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| CU24408B1 (es) | 2014-06-17 | 2019-05-03 | Pfizer | Compuestos de dihidroisoquinolinona sustituida |
-
2015
- 2015-06-05 CU CU2016000180A patent/CU24408B1/es unknown
- 2015-06-05 CR CR20200484A patent/CR20200484A/es unknown
- 2015-06-05 PT PT15730290T patent/PT3157915T/pt unknown
- 2015-06-05 EA EA201692114A patent/EA031892B1/ru unknown
- 2015-06-05 HU HUE15730290A patent/HUE042964T2/hu unknown
- 2015-06-05 SI SI201530698T patent/SI3157915T1/sl unknown
- 2015-06-05 EP EP15730290.2A patent/EP3157915B1/en active Active
- 2015-06-05 PL PL15730290T patent/PL3157915T3/pl unknown
- 2015-06-05 JP JP2016573051A patent/JP6152495B1/ja active Active
- 2015-06-05 RS RS20190512A patent/RS58632B1/sr unknown
- 2015-06-05 MX MX2016016764A patent/MX2016016764A/es active IP Right Grant
- 2015-06-05 CR CR20160574A patent/CR20160574A/es unknown
- 2015-06-05 MA MA40225A patent/MA40225B1/fr unknown
- 2015-06-05 PE PE2016002737A patent/PE20161552A1/es unknown
- 2015-06-05 MY MYPI2016704453A patent/MY185765A/en unknown
- 2015-06-05 EP EP19159058.7A patent/EP3521285A1/en not_active Withdrawn
- 2015-06-05 BR BR112016029612-5A patent/BR112016029612B1/pt active IP Right Grant
- 2015-06-05 AP AP2016009605A patent/AP2016009605A0/en unknown
- 2015-06-05 CN CN201580032058.7A patent/CN107207464B/zh active Active
- 2015-06-05 ME MEP-2019-85A patent/ME03419B/me unknown
- 2015-06-05 SG SG11201609386YA patent/SG11201609386YA/en unknown
- 2015-06-05 LT LTEP15730290.2T patent/LT3157915T/lt unknown
- 2015-06-05 DK DK15730290.2T patent/DK3157915T3/en active
- 2015-06-05 ES ES15730290T patent/ES2721031T3/es active Active
- 2015-06-05 KR KR1020177001230A patent/KR101877187B1/ko active IP Right Grant
- 2015-06-05 UA UAA201611695A patent/UA118380C2/uk unknown
- 2015-06-05 AU AU2015275826A patent/AU2015275826B2/en active Active
- 2015-06-05 MD MDA20160136A patent/MD4820C1/ro active IP Right Grant
- 2015-06-05 GE GEAP201514347A patent/GEP20186933B/en unknown
- 2015-06-05 WO PCT/IB2015/054272 patent/WO2015193765A1/en active Application Filing
- 2015-06-05 NZ NZ726108A patent/NZ726108A/en unknown
- 2015-06-05 TN TN2016000529A patent/TN2016000529A1/en unknown
- 2015-06-15 TW TW104119287A patent/TWI561516B/zh active
- 2015-06-16 UY UY0001036170A patent/UY36170A/es not_active Application Discontinuation
- 2015-06-16 US US14/740,439 patent/US9481666B2/en active Active
- 2015-06-16 CA CA2894298A patent/CA2894298C/en active Active
-
2016
- 2016-09-12 US US15/262,230 patent/US20160376254A1/en not_active Abandoned
- 2016-11-15 IL IL248991A patent/IL248991B/en active IP Right Grant
- 2016-11-29 PH PH12016502378A patent/PH12016502378A1/en unknown
- 2016-12-05 SV SV2016005333A patent/SV2016005333A/es unknown
- 2016-12-19 CL CL2016003246A patent/CL2016003246A1/es unknown
-
2017
- 2017-06-28 US US15/635,648 patent/US20170298048A1/en not_active Abandoned
-
2018
- 2018-10-10 US US16/156,304 patent/US10570121B2/en active Active
-
2019
- 2019-03-28 HR HRP20190604TT patent/HRP20190604T1/hr unknown
- 2019-04-05 CY CY20191100381T patent/CY1121706T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2721031T3 (es) | Compuestos de dihidroisoquinolinona sustituidos | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| CR20170066A (es) | Compuestos aminopirimidinilo como inhibidires de jak | |
| AR101558A1 (es) | Difluoropirrolidinas como moduladores del receptor de orexina | |
| AR110405A1 (es) | Compuestos | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
| AR099677A1 (es) | Compuesto heterocíclico fusionado y su uso para el control de plagas | |
| AR092790A1 (es) | Derivados bencimidazolicos del acido hidroxamico | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| CO2017001178A2 (es) | Derivado de piridona que tiene un grupo tetrahidropiranil metilo | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR105668A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
| CO2018003367A2 (es) | Benzamidas sustituidas con isoxazolina y análogos como insecticidas | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR095421A1 (es) | Moduladores de p2x7 | |
| AR105549A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| MY178370A (en) | Aqueous composition | |
| AR099071A1 (es) | Antagonistas selectivos de nr2b | |
| AR104539A1 (es) | Compuestos cíclicos | |
| PH12018500668A1 (en) | Therapeutic compounds and methods of use thereof | |
| AR081349A1 (es) | Carboxamidas de pirazinilo como fungicidas | |
| AR093827A1 (es) | Agentes antibacterianos de tetrahidroquinolina triciclica | |
| AR096161A1 (es) | Derivados de triazina |